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Available online 29 December 2015Gestational trophoblastic neoplasia (GTN) represents a group of diseases characterized by production of human
chorionic gonadotropin (hCG). Since non-gestational tumorsmay occasionally secrete hCG, histopathological di-
agnosis is important for appropriate clinical management. However, a histopathological diagnosis is not always
available. We therefore investigated the feasibility of extracting cell free DNA (cfDNA) from the plasma of
women with GTN for use as a “liquid biopsy” in patients without histopathological diagnosis. cfDNA was pre-
pared from the plasma of 20 women with a diagnosis of GTN and ﬁve with hCG-secreting tumors of unknown
origin. Genotyping of cfDNA from the patient, genomic DNA from her and her partner and DNA from the
tumor tissue identiﬁed circulating tumor DNA (ctDNA) (from 9% to 53% of total cfDNA) in 12 of 20 patients
with GTN. In one case without a tissue diagnosis, ctDNA enabled a diagnosis of GTN originating in a non-molar
conception and in another a diagnosis of non-gestational tumor, based on the high degree of allelic instability
and loss of heterozygosity in the ctDNA. In summary ctDNA can be detected in the plasma of women with GTN
and can facilitate the diagnosis of both gestational and non-gestational trophoblastic tumors in cases without
histopathological diagnosis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Gestational trophoblastic neoplasia (GTN) is a spectrum of pregnan-
cy related malignancies including invasive molar disease, choriocarci-
noma and the much rarer placental site trophoblastic tumors (PSTT)
and epithelioid trophoblastic tumors (ETT) (Hui et al., 2014). Prior to
the development of cytotoxic chemotherapy these malignant condi-
tions were invariably fatal. However, overall cure rates now exceed
98% due to the development of improved chemotherapeutic regimens
and follow-up protocols (Seckl et al., 2010).
A hallmark of GTN is the production of human chorionic gonadotro-
pin (hCG). Serum hCG levels aid rapid diagnosis and accurate disease
monitoring (Seckl et al., 2013). However, hCG secretion alone is not
always diagnostic of GTN as some non-gestationalmalignancies also se-
crete hCG (Iles et al., 2010). Women with GTN fall into two groups;
(i) those who following evacuation of a molar pregnancy are treated
with a clinical diagnosis of GTN based on rising serum hCG levels and
(ii) those who present with an hCG-secreting tumor. For the second
group histopathological examination of tissue is important for deter-
mining the correct diagnosis and when the diagnosis remains unclear
molecular genotyping can play an important role (Fisher et al., 2007).. This is an open access article underMost histological specimens of trophoblastic neoplasia are obtained
via sampling of disease from the uterus. However GTN may be highly
vascular and biopsy of tissue in the uterus or elsewheremay be deemed
unsafe due to the risk of hemorrhage. Therefore some patients with
metastatic disease, a raised serum hCG and characteristic history, such
as a recent pregnancy,may be treated as a GTNwithout a histological di-
agnosis. This is because it is prudent to treat a highly curable disease,
rather than risk morbidity andmortality via delay to achieve a histolog-
ical diagnosis (Seckl et al., 2013). Patients who have GTNmay therefore
be left with uncertainty regarding their prognosis while patients with
non-gestational tumors may be treated with inappropriate aggressive
chemotherapy. For these women development of a blood based diag-
nostic test would be beneﬁcial.
Circulating cell free DNA (cfDNA) has been investigated in patients
with solid tumors and circulating tumor DNA (ctDNA) is reported to
be detectable in a wide range of malignancies (Bettegowda et al.,
2014). In solid tumors there is evidence that ctDNA is an effective bio-
marker at predicting relapse following surgery (Diehl et al., 2008) and
progression during chemotherapy and targeted therapy (Diaz et al.,
2012). In prenatal screening for aneuploidy, fetal cfDNA obtained from
maternal plasma, has proven to be highly accurate with a detection
rate for trisomy 21 of up to 100% (Norton et al., 2015). Since GTN is
both a malignancy and pregnancy related we would predict cfDNA
from trophoblastic cells to be present in the plasma of patients with
these tumors. Due to the unique genetics of GTN i.e. the presence ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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may be easily detectable. cfDNA may therefore provide unique genetic
information about a patients’ disease hereto unavailable.
This report describes the feasibility of extracting cfDNA from the
plasma of women with GTN, detection of ctDNA within these samples
and utility of cfDNA to act as a “liquid biopsy” to enable the correct diag-
nosis for patientswith hCG-secreting tumors without a tissue diagnosis.
2. Methods
2.1. Patients
Twenty-ﬁve patients were enrolled in the study. All patients were in
their ﬁrst week of admission to the Trophoblastic Screening and
Treatment Centre, Charing Cross Hospital (CXH) to receive chemother-
apy for conﬁrmed or suspected GTN. Patients were split into two groups
according to presentation.
2.2. Group 1: Women with Conﬁrmed GTN
This group included 20 patients, 18 of whom were previously regis-
tered with the Trophoblastic Screening and Treatment Centre, following
a histological diagnosis of molar pregnancy and subsequently admitted
to CXH for chemotherapy following a diagnosis of invasive molar disease.
Two further patients with no previous diagnosis of molar pregnancy pre-
sentedwithmetastatic gestational choriocarcinoma, conﬁrmedonbiopsy,
and were included following admission for curative chemotherapy.
2.3. Group 2: Women with hCG-secreting Tumors of Unknown Origin
This group included ﬁve patients who were referred to CXH with
raised hCG levels and tumors at one or more sites but no histological
diagnosis. All ﬁve patients were treated with a presumptive diagnosis
of GTN. Two of these patients are described below.
2.4. Case CFD-023
A 47 year old female presented with vaginal bleeding. Obstetric his-
tory included two normal male pregnancies 15 and 13 years previouslyTable 1
Non-maternal cfDNA in women with gestational trophoblastic tumors.
Case Serum
hCG (IU/L)
Days since administration
of chemotherapy
Total cfDNA from
3 mL plasma (ng)
Estimated % of c
based on genoty
Post-mole trophoblastic tumors
CFD-001 10,097 1 9.8 0
CFD-002 12,946 6 17.4 0
CFD-003 37,923 6 14.4 0
CFD-004 35,095 3 6.0 18
CFD-005 1497 3 3.2 0
CFD-007 448,650 6 8.6 42
CFD-009 14,884 2 24.2 0
CFD-010 16,326 3 17.1 10
CFD-011 24,622 3 4.4 16
CFD-012 8308 2 5.9 0
CFD-013 133,018 5 22.1 42
CFD-015 20,237 6 8.5 0
CFD-016 30,227 2 16.2 12
CFD-018 238,703 7 4.6 13
CFD-019 53,046 0 5.4 0
CFD-022 47,472 1 4.3 26
CFD-024 150,101 5 14.6 19
CFD-025 169,442 5 10.8 11
Post-term choriocarcinoma
CFD-027 66,861 5 9.3 9
CFD-031 700,855 1 23.7 53
hCG, human chorionic gonadotropin; cfDNA, cell free DNA; ctDNA, circulating tumorDNA; CHMand a termination of pregnancy 11 years ago. Routine chest radiograph
revealed cannon ball lung metastases. Her serum hCG at this point was
374,365 IU/L. Two days following admission the patientwas transferred
to CXH. CT staging revealed a pelvic mass and multiple pulmonary
metastases. MRI head showed a 2 mm brain metastasis. No tissue was
available for diagnosis and her FIGO score was 20. The patient was
initially treated with low dose induction etoposide and cisplatin (EP)
(Agarwal et al., 2014) weekly and once clinically stable was switched
to EP, methotrexate and actinomycin-D for patients with central
nervous system disease (EP-EMA(CNS)) plus intrathecal methotrexate
(MTX) as she had ultra-high risk disease (Seckl et al., 2013).
2.5. Case CFD-008
A 33 year old female presented with abdominal pain and a positive
pregnancy test. Her obstetric history was a normal pregnancy
four years previously and a miscarriage three years ago. Her medical
history was of a T3N1M0 gastric adenocarcinoma successfully treated
18 months previously with neoadjuvant epirubicin, cisplatin, and cape-
citabine chemotherapy. Shewas initiallymanaged locally as a suspected
ectopic pregnancy but her serum hCG climbed to N200,000 IU/L. A
computed tomography scan showed widespread liver metastases and
she was therefore transferred to CXH. Further imaging revealed no
other abnormalities. No tissue was available for conﬁrmation of the
clinical diagnosis of GTN and her FIGO score was 21. Initial treatment
was with EP-EMA(CNS) plus intrathecal MTX.
2.6. Preparation of Plasma
Plasma was separated from whole blood by centrifugation at
1900×g for 10min at 4 °C. The plasma layerwas separated and a further
centrifugation step at 16,000 ×g for 10 min was included. Plasma was
stored at−80 °C until analysis.
2.7. cfDNA Preparation
cfDNA was prepared from 3mL plasma according to manufacturer's
instructions using a QIAamp circulating nucleic acid kit (Qiagen, UK).fDNA that is ctDNA
ping
Estimated
ctDNA (ng)
Diagnosis based
on ctDNA
Genotype of antecedent
molar pregnancy
–
–
–
1.08 GTN; post-CHM Androgenetic, monospermic
–
3.61 GTN; post-CHM Androgenetic, monospermic
–
1.71 GTN; post-CHM Not available
0.70 GTN; post-CHM Androgenetic, monospermic
–
9.28 GTN; post-CHM Not available
–
1.94 GTN; post-CHM Androgenetic, dispermic
0.60 GTN; post-CHM Androgenetic, monospermic
–
1.11 GTN; post-CHM Androgenetic, monospermic
2.78 GTN; post-CHM Androgenetic, monospermic
1.19 GTN; post-CHM Androgenetic, dispermic
0.84 GTN NA
12.60 GTN; post-male NA
, complete hydatidiformmole; GTN, gestational trophoblastic neoplasia;NA, not applicable.
Table 2
Non-maternal cfDNA in women with hCG-secreting tumors of unknown origin.
Case Serum hCG
(IU/L)
Reproductive
history
Total cfDNA from 3 mL plasma
(ng)
Estimated % of cfDNA that is ctDNA based on
genotyping
Estimated ctDNA
(ng)
Diagnosis based on
ctDNA
CFD-008 239,171 FTNDF, miscarriage 123.0 65 79.95 Non-gestational tumor
CFD-014 5254 FTNDM 14.1 – – –
CFD-017 6 No known pregnancy 28.8 – – –
CFD-023 372,117 FTNDM, FTNDM, TOP 118.0 44 51.92 Post-term tumor (female)
CFD-026 725 No known pregnancy 15.7 – – –
FTNDF, full term normal delivery of female; FTNDM, full term normal delivery of male; TOP, termination of pregnancy; cfDNA cell free DNA; ctDNA circulating tumor DNA.
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Technologies, UK).2.8. Genomic DNA Preparation
DNAwas prepared from 200 μL of patient's blood, and where possi-
ble their partner, using a QIAamp DNA mini kit (Qiagen, UK) as per the
manufacturers protocol.Fig. 1. Partial genotype of cfDNA, DNA from the patient, her partner, and the CHM in two cases
sample and the antecedent CHM, at the D3S1358 locus in addition to two maternally derived (
(2656 and 1745 units) provides an estimate of the ctDNA of 45% (3626/8027). Relative peak he
(2065/4595). (b) Case CFD-016 showing a single paternally derived (solid) peak in addition to
relative heights of the peaks at the THO1 and D13S317 locus give an estimated percentage of ct
obtained when area under the peak, rather than peak height, was used to estimate ctDNA.2.9. DNA Preparation from Tissue
Trophoblastic tissue and adjacentmaternal tissuewere dissected in-
dependently from 3 to 5 unstained 5 μm sections of formalin-ﬁxed
parafﬁn-embedded (FFPE) tissue, with reference to a Hematoxylin and
Eosin stained section. DNA was prepared using a QIAmp DNA FFPE
Tissue Kit (Qiagen, UK) according to the manufacturer's protocol and
the DNA stored at -20 °C until analysis.of post-mole GTN. (a) Case CFD-007 showing a single (solid) peak, found in the paternal
open) peaks. The relative height of the paternal peak (3626 units) and the maternal peaks
ights of 2065, 1400 and 1129 units at the THO locus also give an estimate of ctDNA of 45%
a single, or two, maternal (open) peak(s) at the THO1 and D13S317 loci respectively. The
DNA of 11% (650/6060) and 15% (509/3595) respectively in this case. Similar results were
Fig. 2.Partial genotype of cfDNA,DNA from thepatient, her partner and the tumor tissue in
case CFD-031. The presence of a Y chromosome, represented by the solid peak for the
amelogenin (AMEL) locus, conﬁrms a paternal contribution to the cfDNA. At the
D3S1358 loci a single paternally derived allele (solid peak) is present together with two
maternally derived alleles (open peaks), the disproportionate areas under these two
peaks indicating that one maternally derived peak comprises DNA from both ctDNA and
maternal cfDNA. The higher maternal peak represents ctDNA and cfDNA of maternal
origin in the same ratio as the solid peak representing only ctDNA (5735 units) and the
lower maternal peak representing only cfDNA of maternal origin (2919 units) providing
an estimate of percentage ctDNA of 66% (5735/8674).
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1 μL DNA was ampliﬁed with primers for 15 short tandem repeat
(STR) loci on 13 chromosomes, plus the amelogenin locus, using an
AmpFlSTR Identiﬁler Plus kit (Applied Biosystems, Warrington, UK).
PCR products were resolved by capillary electrophoresis using an ABI
3100 Genetic Analyzer and genotypes determined using GeneMapper
version 4.0 software (Applied Biosystems, Warrington, UK).
Where non-maternal alleles were present in the ampliﬁed cfDNA
and were consistent with the presence of ctDNA originating from a
molar pregnancy, the percentage of DNA attributable to themolar tissue
was estimated by calculating the height of the peak(s) for the paternal
allele(s) as a proportion of the sum of the allele heights for all alleles
at that locus. The proportion of ctDNAwas calculated for three informa-
tive loci and the average recorded. Where a paternal allele was present
and disproportionate heights of the maternal alleles suggested the
ctDNA originated in a non-molar pregnancy, the percentage of ctDNA
was estimated from the relative height of the paternal allele to the
sum of the paternal allele plus the smaller maternal allele, representing
cfDNA of maternal origin. Again the average for three informative loci
was recorded.
2.11. Statistics
The yield of ctDNA and serum hCG levels were compared using
Spearman's correlation analysis with a p value b0.05 being considered
signiﬁcant.
2.12. Ethics
The project was approved (project no. R14021) by the Tissue
Management Committee of the Imperial College Healthcare NHS Trust
Research Tissue Bank which is approved by NRES to provide deemed
ethics for projects associatedwith the Research Tissue Bank. All patients
in the study and their partners consented to providing additional blood
samples.
2.13. Role of the Funding Source
Funding and resources were provided by the Trophoblastic Screening
and Treatment Centre, Charing Cross Hospital, London, UK, the National
Institute for Health Research (NIHR) Imperial Biomedical Research Centre
and the Imperial Experimental Cancer Medicine Centre. The funding
sources played no role in the design, completion or decision to publish
this article.
3. Results
3.1. Extraction of cfDNA from Plasma
cfDNA was detectable in all 25 cases. Total cfDNA extracted from
3 mL of plasma ranged from 3.2 to 123.0 ng (Tables 1, 2).
3.2. cfDNA in Women with Conﬁrmed GTN
cfDNA was detectable in all 20 cases with GTN. In these 20 cases the
total cfDNA extracted from 3 mL plasma ranged from 3.2 to 24.2 ng
(Table 1). Of the 18 cases of known post-mole GTN, genotyping of the
cfDNA in ten (56%) revealed alleles of non-maternal origin, consistent
with ctDNA originating in CHM. In eight cases genotyping of the ante-
cedent molar pregnancy conﬁrmed this as the origin of the ctDNA
(Table 1; Fig. 1). The percentage of detectable ctDNA ranged from 10%
to 42% of the total cfDNA (Table 1) while total ctDNA ranged from 0.6
to 9.28 ng.
ctDNA was detectable in both patients with choriocarcinoma
diagnosed on routine histopathology (Table 1). In case CFD-031 anestimated 53% of the cfDNA was tumor in origin (Fig. 2). A greater pro-
portion of cfDNA for one of the two maternal alleles at informative loci,
and the presence of DNA from a Y chromosome demonstrated that this
tumor had arisen in a previous male pregnancy. This was conﬁrmed by
genotyping of DNA from the tumor tissue (Fig. 2). In case CFD-027 the
proportion of cfDNA attributable to the tumorwas small (9%). Although
non-maternal alleles could be identiﬁed in the cfDNA, the high level of
cfDNA from the patient's own cells obscured any potential maternal
contribution to the tumor genotype and so, although clearly gestational,
it was not possible to determine whether the causative pregnancy had
been a normal conception or an androgenetic CHM.
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The presence of ctDNA in women with GTN was found to be associ-
ated with serum hCG levels. No ctDNA was detected in cases where
serum hCG levels were 14,884 IU/L or below; ctDNA was detectable,
but not consistently, in serum hCG levels between 16,326–53,046 IU/L
while ctDNA was consistently detected at serum hCG levels of
66,861 IU/L and above (Table 1). For women with GTN Spearman's
rank correlation coefﬁcient showed a signiﬁcant correlation between
serum hCG concentrations and ctDNA (rho = 0.69; 95% CI 0.35 to
0.87; p = 0.001).
3.4. cfDNA in Women with hCG-secreting Tumors of Unknown Origin
In threewomenwith tumors of unknown origin, the genotype of the
cfDNA was the same as that of the patient. In two further cases
non-maternal cfDNA was present enabling a diagnosis to be made
(Table 2) and these are discussed in further detail.
3.5. Case CFD-023
Analysis of cfDNA extracted from plasma taken before chemothera-
py, detected paternal alleles in the cfDNA, in addition to both maternal
alleles, thereby conﬁrming the presence of a gestational tumor
(Fig. 3). For D21S11 and other loci, not shown, the two maternal alleles
were present at different heights suggesting one was derived from
maternal cfDNA and the other made up of maternal cfDNA and ctDNA.
The genotype of the tumor is therefore consistent with an origin in a
pregnancy from a normal, non-molar conception with both a maternal
and paternal contribution to the genome. Genotyping at the AMEL
locus showed all the cfDNA to be from the X-chromosome (Fig. 3) and
therefore unlikely to have originated in either of her full term male
pregnancies. The tumor was most likely to have originated in herFig. 3. Partial genotype of cfDNA, DNA from the patient, and fromher partner in case CFD-023. A
242 units for loci D21S11 and D7S820 respectively. The disproportionate heights of the two
maternal cfDNA. The percentage cfDNA was calculated as above giving an estimate for percen
showed that all the cfDNA has an XX gender and does not contain a Y chromosome, indicatingterminated pregnancy, which was presumably female. This patient has
ongoing response to primary chemotherapy.
3.6. Case CFD-008
Analysis of cfDNA extracted post chemotherapy revealed no alleles
in the cfDNA that were not found in the patient indicating an absence
of any contribution to the tumor genome from her partner. However,
the genotype of the cfDNA was very different to that of the patient
showing a high degree of allelic instability and some loss of heterozy-
gosity when compared to the patient's genotype (Fig. 4), suggesting
that a high proportion of the cfDNA was in fact ctDNA. The absence of
alleles other than those in the patient was consistent with a tumor of
non-gestational origin. There was an initial complete radiological
response to chemotherapy but her hCG began to rise 5 months later.
Genotyping of tissue from a subsequent liver biopsy showed a very sim-
ilar pattern to that of the cfDNA (Fig. 4) conﬁrming that the cfDNA
contained ctDNA that was non-gestational in origin. An additional allele
seen in the later biopsy, at locus D13S317, suggests further instability
and some tumor heterogeneity between the ctDNA and biopsied tissue.
Following a histological diagnosis of non-gestational disease the patient
switched to palliative treatment and died one month later.
4. Discussion
Analysis of ctDNA is currently being introduced as a non-invasive
method for detecting and monitoring the progress of a number of can-
cers (Bettegowda et al., 2014; Crowley et al., 2013). In this study we
have demonstrated that ctDNA can be detected in the plasma of
women with trophoblastic tumors and can facilitate diagnosis.
Screening using fetal cfDNA frommaternal blood samples is increas-
ingly used for prenatal diagnosis (Bianchi, 2012; Nicolaides et al., 2014).
While cfDNA is usually cleared rapidly after delivery (Lo et al., 1999) we
speculated that cfDNA would persist in women with invasive molarpaternal contribution to the cfDNA is represented by a single allele (solid peak) of 540 and
maternal alleles at the D21S11 locus indicate that one peak represents both ctDNA and
tage ctDNA of 44% (540/1237) in this case. Genotyping of the amelogenin locus (AMEL)
that the tumor had originated in a female pregnancy.
Fig. 4. Partial genotype of cfDNA, DNA from the patient, her partner and a subsequent DNA sample from a liver metastasis in case CFD-008.While all alleles in the cfDNA (solid peaks) are
present in the patient's DNA the proportion of each allele is very different suggesting that, where there are two alleles, the lower peak in each case represents cfDNA from the patientwhile
the higher peak representsmostly ctDNA. The contribution ofmaternal cfDNA to the higher peakwould be expected to be similar to that of the lower peak. ctDNA is therefore represented
by the height of the higher peak less the lower peak for informative markers, (8058–1356 units), 71% of the total cfDNA, for the THO1 locus.
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of the pregnancy in these cases. This study has shown that for the ma-
jority of women who develop trophoblastic tumors, there is sufﬁcient
ctDNA in patients' blood to be detected bymolecular genotyping, a tech-
nique routinely used in clinical diagnosis of trophoblastic disease
(Fisher et al., 2007, 2014).
Both the total cfDNA extracted from3mLof plasma, 3.2–24.2 ng, and
the proportion of total cfDNA that derived from the molar pregnancy,
0–42%,were highly variable. In other tumor types the level of detectable
ctDNA has been reported to relate to the extent of disease (Diehl et al.,
2008; Dawson et al., 2013; Kim et al., 2014). Since serum hCG levels re-
ﬂect tumor burden in GTN (Seckl et al., 2010, 2013), the yield of ctDNA
might be expected to parallel serum hCG levels. The yield of ctDNA
reﬂected tumor burden in that ctDNA was detectable in all patients
with a serum hCG of 66,861 IU/L and above but undetectable where
serum hCGwas 14,884 IU/L or below.While Spearman's correlation co-
efﬁcient for serum hCG levels and yields of ctDNA was signiﬁcant in
women with GTN overall, there were a group of women with serum
levels between 16,326 IU/L and 53,046 IU/L where detection of ctDNA
was variable, suggesting that the release of ctDNA from tumors follow-
ing chemotherapy may reﬂect other aspects of tumor biology and not
simply tumor burden. Further studies analyzing ctDNA levels pre- and
post-chemotherapy at speciﬁc time points are needed to investigate
the exact relationship between serum hCG levels and ctDNA yields.With the rare exception of a small number of PSTT and ETT, all GTN
produce hCG. While hCG production is a characteristic of all GTN, a
number of other tumor subtypes have been shown to secrete hCG rang-
ing from 4% in prostate cancer to as high as 76% of bladder tumors (Iles
et al., 2010). For most of these tumors other clinicopathological features
are likely to lead to a diagnosis but for women of reproductive age with
raised serumhCG and nopathological diagnosis, the differential diagno-
sis may be between a GTN and a non-gestational, hCG-secreting
malignancy (Fisher et al., 2007). In two of ﬁve cases of women with
hCG-secreting tumors of unknown origin in the present series, genotyp-
ing of cfDNA was helpful in establishing a diagnosis. In one patient the
presence of ctDNA enabled a diagnosis of a GTN originating in a female
pregnancy. In the other genotyping of ctDNA showed gross microsatel-
lite instability consistentwith ctDNA from a non-gestational tumor. The
samemicrosatellite instability was demonstrated in the liver metastasis
that was later biopsied indicating the unequivocal origin of the cfDNA
from the tumor. These two cases demonstrate the utility of cfDNA to
provide a ‘liquid biopsy’ to aid diagnosis when histology is unavailable
and that genotyping can potentially diagnose both gestational and
non-gestational trophoblastic tumors.
In three cases of tumor of unknown origin it was not possible to
make a speciﬁc genetic diagnosis as all cfDNA had an identical genotype
to the patient. It is possible that ctDNAwas present and that the tumors
were non-gestational but as the ctDNA showed no instability at the loci
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was conﬁrmed in one case (CFD 017) in which genotyping of the tumor
tissue, from a subsequent biopsy, showed the tumor to be non-
gestational with a genotype identical to the patient for those loci ana-
lyzed. Alternatively ctDNA may have been below the level of detection
in these cases as all three patients had very low levels of serum hCG.
While genotyping using short tandem repeat polymorphisms is
relatively straightforward other techniques such as droplet digital PCR
(Hudecova, 2015), in combination with single nucleotide polymor-
phisms (Matsuda and Honda, 2015), might provide a more sensitive
approach for identifying ctDNA in women with low serum hCG.
Conversely the absence of paternal alleles in a patient with a high
level of serum hCG might suggest a non-gestational tumor. Further
studies are needed tomore accurately determine the current sensitivity
of genotyping assays for this type of analysis.
While genotyping is useful in the differential diagnosis of gestational
and non-gestational trophoblastic tumors, it does not distinguish
choriocarcinoma from themuch rarer PSTT or ETT, which have a poorer
prognosis and may require different therapeutic approaches (Lurain,
2011). cfDNA from patients with PSTT or ETT could provide ctDNA
which together with next generation sequencing ormicroarray analysis
might enable identiﬁcation of speciﬁc genetic alterations associated
with these tumor types. Such biomarkers would potentially provide a
means of monitoring response in these rare tumors for which serum
hCG levels may be less informative than for the more common GTN,
choriocarcinoma (Moutte et al., 2013).
Identiﬁcation of biomarkers that could identify women in whom
molar pregnancy will not resolve spontaneously following termination
or biomarkers that predict resistant disease are important objectives
in GTNmanagement. cfDNAhas enabled tracking of speciﬁc knownmu-
tations and identiﬁcation of de-novo mutations in other tumor types
(Frenel et al., 2015; Patel and Tsui, 2015; Thierry et al., 2014). ctDNA
from women with GTN together with advancements in modern tech-
nology, that enable analysis of very small DNA samples, offers the po-
tential to provide answers to these questions.
This study has shown that ctDNA can be extracted fromwomenwith
GTN and can act as a liquid biopsy enabling diagnosiswhen a histopath-
ological diagnosis is not available. While these observations need to be
validated in larger studies, the ability to isolate ctDNA from GTN offers
the potential for improved diagnosis, more personalized monitoring of
disease, and a resource to investigate and expand our knowledge of
this rare group of tumors.
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